Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1592247 | 1.00 | CBLB (0.34) | CBLB | |
| SCHEMBL5214449 | 0.90 | — | — | |
| SCHEMBL2791966 | 0.85 | MEN1 (0.44) | — | |
| SCHEMBL5498778 | 0.84 | POLB (0.40) | — | |
| SCHEMBL1401053 | 0.82 | PLA2G2A (0.36) | CBLB | |
| SCHEMBL9339015 | 0.79 | CBLB (0.41) | CBLB | |
| SCHEMBL5493627 | 0.76 | POLB (0.38) | — | |
| SCHEMBL3773863 | 0.76 | PLA2G2A (0.36) | CBLB | |
| SCHEMBL1401179 | 0.76 | PLA2G2A (0.36) | CBLB | |
| SCHEMBL5502331 | 0.74 | POLB (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812394-A2 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS | Matrix Laboratories Ltd (IN) | 2007-08-01 | — | — | EP | claimed |
| WO-2006008751-A2 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS | MATRIX LABORATORIES LTD (IN) | 2006-01-26 | — | — | WO | claimed |
| US-20110137039-A1 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS | MYLAN LABORATORIES LIMITED (IN) | 2011-06-09 | — | — | US | disclosed |
| EP-1812394-B1 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS | MATRIX LAB LTD (IN) | 2011-03-02 | — | — | EP | disclosed |
| US-20090143590-A1 | Process for the Preparation of Montelukast and its Salts | MATRIX LABORATORIES LTD. (IN) | 2009-06-04 | — | — | US | disclosed |
| EP-1812394-A2 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS | Matrix Laboratories Ltd (IN) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006008751-A2 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS | MATRIX LABORATORIES LTD (IN) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143590-A1 | Process for the Preparation of Montelukast and its Salts | CMA1, CYSLTR1, CYSLTR2 | CBLB 4465/4885 |
| US-20110137039-A1 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS | MPST, CMA1, LTC4S | CBLB 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.